Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells
about
Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic ApplicationsTranscellular targeting of fiber- and hexon-modified adenovirus vectors across the brain microvascular endothelial cells in vitroTraceless bioresponsive shielding of adenovirus hexon with HPMA copolymers maintains transduction capacity in vitro and in vivoAdenoviral Vectors for Hemophilia Gene TherapyHexon hypervariable region-modified adenovirus type 5 (Ad5) vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectorsEncapsulation of adenovirus serotype 5 in anionic lecithin liposomes using a bead-based immunoprecipitation technique enhances transfection efficiency.Helper-dependent adenoviral vectors for liver-directed gene therapy.miRNA-mediated silencing in hepatocytes can increase adaptive immune responses to adenovirus vector-delivered transgenic antigensSystemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model.Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors.Covalent decoration of adenovirus vector capsids with the carbohydrate epitope αGal does not improve vector immunogenicity, but allows to study the in vivo fate of adenovirus immunocomplexesReal-time recording of circadian liver gene expression in freely moving mice reveals the phase-setting behavior of hepatocyte clocks.Adenovirus Vector-Derived VA-RNA-Mediated Innate Immune Responses.CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter.Tumor growth and metastasis suppression by Glipr1 gene-modified macrophages in a metastatic prostate cancer model.Helper-Dependent Adenoviral Vectors.Advances and future challenges in adenoviral vector pharmacology and targeting.Manipulation of adenovirus interactions with host factors for gene therapy applications.Liver cell-targeted delivery of therapeutic molecules.Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses.Gene therapy with helper-dependent adenoviral vectors: lessons from studies in large animal models.Oncolytic viruses: adenoviruses.Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5.PEGylated helper-dependent adenoviral vector expressing human Apo A-I for gene therapy in LDLR-deficient mice.Adenovirus immunity: X marks the spot.Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement.Magnetic nanoparticles enhance adenovirus transduction in vitro and in vivo.Challenges and Prospects for Helper-Dependent Adenoviral Vector-Mediated Gene Therapy.
P2860
Q26776553-B2C13F79-7F44-46F2-8C2D-CC88500335C1Q28484085-D99C7101-65BF-461C-9FF5-1A0BDD565A09Q28539158-B7E3089C-7F83-437A-A688-BE3C0EC5BE37Q33690648-E9474F8B-FE40-4848-AFC8-7A5134998A59Q34057708-634BF494-341F-4B5D-B4C9-3812B80FF9B1Q34146469-B4743124-C680-4F28-B524-4096501B40CCQ34982825-4B9A2922-3DDF-4C83-AB77-02F366D21911Q35144457-661B3934-64E4-4795-9170-08D661328F65Q35226101-3419BB45-5E32-4AC0-8F73-3316D45A685FQ35826589-FD75B3DD-43C8-4BF7-AE3E-7EC55FB812DCQ36363270-8C071BD7-FB24-4C07-8BA0-F8A0E48EA42EQ37019229-8970A4BF-C3EB-45BA-852A-2C7D641E1B79Q37378133-4E6935AA-F256-4178-B518-994B2B227CB3Q37420781-5C2B22EE-DB7D-4114-86E1-EDEAA00412A0Q37436531-1652FD4D-94C4-4FFD-AB51-0E0FA0E296EDQ37582126-961EB139-B58F-4D13-86F4-427B72EC3C4CQ37859842-4014F359-4A51-4B89-BBC1-9057293DDB55Q37984486-8D891EBF-0C24-4C54-BFB1-4DB9A3F50D72Q38229624-A3286479-A281-4350-A3CF-66F0E9FE2109Q39342777-86625E2B-B364-4EC3-A9D3-757AFD032CA5Q39358889-7E6DFB3C-CB38-4F4A-80AC-B3D3334CAF54Q39432063-E0786679-E87E-4BF7-BCF7-E778A00544E6Q40103248-0480FD04-14CA-474D-8064-F9366B21E049Q42281690-CF0825D4-2678-40D8-94A5-AB4FCE753AF1Q42407536-9201AF5F-F7C6-49E1-95E7-747ED34F959FQ44368424-58514589-045E-48FA-8B9F-D0B7E3025ABEQ45875626-3BF78E41-EA7D-43AD-902B-4D0093652321Q50977875-65BCEF33-9FED-46A5-8129-623E091F0058
P2860
Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Modifications of adenovirus he ...... ial evasion from Kupffer cells
@ast
Modifications of adenovirus he ...... ial evasion from Kupffer cells
@en
Modifications of adenovirus he ...... ial evasion from Kupffer cells
@nl
type
label
Modifications of adenovirus he ...... ial evasion from Kupffer cells
@ast
Modifications of adenovirus he ...... ial evasion from Kupffer cells
@en
Modifications of adenovirus he ...... ial evasion from Kupffer cells
@nl
prefLabel
Modifications of adenovirus he ...... ial evasion from Kupffer cells
@ast
Modifications of adenovirus he ...... ial evasion from Kupffer cells
@en
Modifications of adenovirus he ...... ial evasion from Kupffer cells
@nl
P2093
P2860
P356
P1433
P1476
Modifications of adenovirus he ...... ial evasion from Kupffer cells
@en
P2093
Amanda Rosewell
Donna Palmer
Erika Schmidt
Florian Kreppel
Francesco Vetrini
Jan-Michael Prill
Nathan Grove
Sigrid Espenlaub
Stefan Kochanek
P2860
P356
10.1038/MT.2010.229
P577
2010-10-19T00:00:00Z